Pluri Inc. Faces Delisting Concerns

TL;DR

Pluri Inc. might get delisted - big trouble for shareholders.

AI Summary

Pluri Inc. filed an 8-K on January 21, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was on January 15, 2025. The company, formerly known as Pluristem Therapeutics Inc., is incorporated in Nevada and based in Haifa, Israel.

Why It Matters

This filing indicates potential issues with Pluri Inc.'s compliance with stock exchange listing requirements, which could lead to its shares being delisted.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the liquidity and value of the company's stock.

Key Players & Entities

• Pluri Inc. (company) — Registrant
• January 21, 2025 (date) — Filing Date
• January 15, 2025 (date) — Earliest Event Date
• Pluristem Therapeutics Inc. (company) — Former Company Name
• Nevada (jurisdiction) — State of Incorporation

FAQ

Key Financial Figures

• $0.00001 — h registered Common Shares, par value $0.00001 per share PLUR The Nasdaq Capital M
• $2,500,000 — es the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued l
• $35 million — value of listed securities of at least $35 million or net income of $500,000 from continui
• $500,000 — f at least $35 million or net income of $500,000 from continuing operations in the most

Filing Documents

• ea0227893-8k_pluri.htm (8-K) — 30KB
• 0001213900-25-004755.txt ( ) — 201KB
• plur-20250115.xsd (EX-101.SCH) — 3KB
• plur-20250115_lab.xml (EX-101.LAB) — 33KB
• plur-20250115_pre.xml (EX-101.PRE) — 22KB
• ea0227893-8k_pluri_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to Satisfy a Continued

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on November 25, 2024, Pluri Inc., or Pluri or the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on The Nasdaq Capital Market, or the Stockholders' Equity Requirement, nor is it in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. On January 6, 2025, the Company submitted a plan to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq has determined to grant the Company an extension of time to regain compliance with the Stockholders' Equity Requirement until May 24, 2025. If the Company fails to evidence compliance by the required deadline, the Company may be subject to delisting. At that time, the Company may appeal Staff's determination to a Hearings Panel. The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance the Company will ultimately regain compliance with all applicable requirements for continued listing. Neither the Nasdaq Letter nor the Company's noncompliance have an immediate effect on the listing or trading of the Company's common shares, which will continue to trade on The Nasdaq Capital Market under the symbol "PLUR".

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses its potentially regaining compliance with Nasdaq's continued listing requirements, and the timing and effect thereof. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: Pluri may not be able to complete a financing transaction on favorable terms, in a timely manner or at all; changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of P

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLURI INC. Date: January 21, 2025 By: /s/ Liat Zalts Name: Liat Zalts Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR